Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Some of the most common functional groups that are amenable to prodrug design include carboxylic, hydroxyl, amine, phosphate/phosphonate and carbonyl groups.